E
About
Veracyte is a leading precision oncology company offering a portfolio of genomic cancer diagnostic tests powered by the Veracyte Diagnostics Platform, which incorporates AI-assisted data mining and broad genomic assays. Designed to give oncologists and other clinicians actionable molecular insights, Veracyte's tests help answer critical clinical questions such as whether a patient can avoid unnecessary surgery, what therapy is optimal, and how long between monitoring intervals is appropriate. Their test portfolio includes: Afirma® Genomic Sequencing Classifier for thyroid cancer, the Decipher® Prostate and Bladder Genomic Classifiers for urologic cancers, Prosigna® Breast Cancer Assay, and the Percepta® Nasal Swab Test for lung cancer. With over 800,000 patients served, Veracyte combines extensive clinical data with a robust evidence generation engine to support precision cancer care globally. The platform is designed for both US-based CLIA lab workflows and international in-vitro diagnostic (IVD) distribution, enabling global access to molecular diagnostics. Clinicians can access results through dedicated portals (Decipher Portal and Afirma Portal). Veracyte also invests heavily in collaborative clinical research and MRD (Minimal Residual Disease) technology, making it a forward-looking platform for the future of cancer diagnostics.
Key Features
- AI-Assisted Genomic Data Mining: The Veracyte Diagnostics Platform uses AI to mine broad genomic assay data, generating deeper molecular insights from cancer specimens than standard pathology alone.
- Multi-Cancer Test Portfolio: Offers clinically validated genomic tests across five cancer types—thyroid (Afirma), prostate and bladder (Decipher), breast (Prosigna), and lung (Percepta).
- Clinical Evidence Generation Engine: A robust engine for generating and publishing clinical evidence supports oncologists with peer-reviewed data to back diagnostic and treatment decisions.
- Physician Portals for Results Access: Dedicated Decipher Portal and Afirma Portal provide clinicians with fast, secure access to patient genomic test results and clinical insights.
- Global Diagnostic Access: Available via centralized CLIA labs in the US and distributed IVD products internationally, making precision diagnostics accessible to patients worldwide.
Use Cases
- Helping oncologists determine whether a thyroid nodule patient can safely avoid surgery using the Afirma Genomic Sequencing Classifier.
- Stratifying prostate cancer risk post-diagnosis with the Decipher Prostate Genomic Classifier to guide treatment intensity decisions.
- Assessing bladder cancer genomics with Decipher Bladder to inform therapy selection and monitoring frequency.
- Guiding adjuvant chemotherapy decisions for early-stage breast cancer patients using the Prosigna assay.
- Screening high-risk lung cancer patients non-invasively via the Percepta Nasal Swab Test to support early detection strategies.
Pros
- Clinically Validated Across Multiple Cancers: Each test is backed by extensive peer-reviewed clinical evidence, giving oncologists confidence in genomic insights for critical treatment decisions.
- Helps Avoid Unnecessary Procedures: Genomic classifiers like Afirma and Decipher can indicate when watchful waiting or less invasive approaches are appropriate, sparing patients unnecessary surgery.
- Scalable Global Platform: The dual CLIA/IVD model allows Veracyte to reach patients in the US and internationally, broadening access to precision cancer diagnostics.
Cons
- Limited to Specific Cancer Types: Currently covers five cancer areas; clinicians managing other cancer types cannot leverage Veracyte's genomic testing portfolio.
- Enterprise and Clinical Setting Only: Tests are ordered and interpreted by healthcare providers in clinical settings—not directly accessible to individual patients or consumers.
- Pricing Not Publicly Listed: As an enterprise medical diagnostic service, pricing and reimbursement depend on insurance coverage and institutional agreements, which can vary significantly.
Frequently Asked Questions
What cancers does Veracyte's genomic testing cover?
Veracyte offers tests for thyroid (Afirma), prostate and bladder (Decipher), breast (Prosigna), and lung (Percepta) cancers.
How does AI play a role in Veracyte's diagnostics?
The Veracyte Diagnostics Platform uses AI-assisted data mining on broad genomic assay data to extract deeper molecular insights, improving diagnostic accuracy and clinical utility.
How can clinicians access patient test results?
Results are available through dedicated online portals—Decipher Portal for urologic cancers and Afirma Portal for thyroid—providing secure, timely access to genomic reports.
Is Veracyte available outside the United States?
Yes. Veracyte supports global markets through distributed in-vitro diagnostic (IVD) products alongside its US-based centralized CLIA laboratory operations.
How many patients have been served by Veracyte's tests?
Veracyte has served over 800,000 patients with its genomic cancer diagnostic tests as of the latest company data.
